| Bioactivity | EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) and other neoplasms and its expression enhances tumorigenicity. EGFRvIII peptide TFA represents a truly tumor-specific target for antitumor immunotherapy[1]. |
| Name | EGFRvIII peptide (PEPvIII) (TFA) |
| Sequence | Leu-Glu-Glu-Lys-Lys-Gly-Asn-Tyr-Val-Val-Thr-Asp-His-Cys |
| Shortening | LEEKKGNYVVTDHC |
| Formula | C72H112F3N19O26S |
| Molar Mass | 1748.83 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Schmittling RJ, et al. Detection of humoral response in patients with glioblastoma receiving EGFRvIII-KLH vaccines. J Immunol Methods. 2008 Nov 30;339(1):74-81. |
EGFRvIII peptide (PEPvIII) (TFA)
CAS: F: C72H112F3N19O26S W: 1748.83
EGFRvIII peptide (PEPvIII) TFA is a tumor-specific mutation that is widely expressed in glioblastoma multiforme (GBM) an
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.